OpenAI invests in Sam Altman’s brain computer interface startup Merge Labs

In an intriguing development within the tech industry, OpenAI has made a significant investment in Merge Labs, a brain-computer interface startup founded by Sam Altman, the CEO of OpenAI. This startup, which emerged from stealth mode recently, aims to meld biological and artificial intelligence to enhance human capabilities. The recent seed funding round raised $250 million, with OpenAI reportedly contributing the most substantial portion, valuing Merge Labs at an impressive $850 million. Merge Labs believes that by interfacing with the brain's neurons, they can restore lost abilities, foster healthier mental states, and deepen human connections, all while expanding our creative potential alongside advanced AI. The company plans to achieve these ambitions through non-invasive technologies that utilize molecular methods rather than traditional electrodes, employing techniques such as ultrasound to facilitate communication with neurons. This investment further intensifies the rivalry between Altman and Elon Musk, whose Neuralink is also at the forefront of developing brain-computer interfaces (BCIs). Unlike Merge Labs, Neuralink requires invasive surgical procedures to implant its devices, which involves significant risks. While both companies aim to improve the lives of individuals with severe disabilities, Merge Labs appears to focus more on the aspirational goal of merging human biology with AI to unlock superhuman capabilities. OpenAI has articulated its vision for the future of BCIs, emphasizing their potential to revolutionize communication and interaction with technology, making it more human-centric. Altman has surrounded himself with experienced co-founders for Merge Labs, including Alex Blania and Sandro Herbig, who are also involved with Tools for Humanity, and other experts from the neural tech field. As part of this partnership, OpenAI plans to collaborate with Merge Labs on foundational scientific models and advanced tools to expedite research and development. By leveraging AI to enhance bioengineering and neuroscience, the startup could serve as a powerful interface for OpenAI's software. The investment aspect of this deal reflects a cyclical relationship: if Merge Labs thrives, it could drive user engagement for OpenAI, further validating its investment in the startup. Furthermore, Altman's vision for a future where humans and machines coexist harmoniously has been a long-standing ambition for him, dating back to 2017. As this exciting venture unfolds, both OpenAI and Merge Labs are set to explore uncharted territories in the realm of brain-computer interfaces, potentially changing the fabric of human interaction with technology. TechCrunch is awaiting further insights from both entities regarding their future plans and developments.